Inmunogenética e inmunología de las mucosas
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublikationen in Zusammenarbeit mit Forschern von AstraZeneca (United Kingdom) (1)
2020
-
Combined MEK and PI3K/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features
Cancer Research, Vol. 80, Núm. 4, pp. 843-856